Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic, disabling bladder disease, with an uncertain pathophysiology and no universally effective treatment.
To evaluate the efficacy and safety of certolizumab pegol compared with placebo in women with refractory IC/BPS.
